Department of Pediatrics, New York University School of Medicine, New York, NY 10016, USA.
Int J Obes (Lond). 2013 Jan;37(1):16-23. doi: 10.1038/ijo.2012.132. Epub 2012 Aug 21.
To examine the associations of antibiotic exposures during the first 2 years of life and the development of body mass over the first 7 years of life.
Longitudinal birth cohort study.
A total of 11 532 children born at 2500 g in the Avon Longitudinal Study of Parents and Children (ALSPAC), a population-based study of children born in Avon, UK in 1991-1992.
Exposures to antibiotics during three different early-life time windows (<6 months, 6-14 months, 15-23 months), and indices of body mass at five time points (6 weeks, 10 months, 20 months, 38 months and 7 years).
Antibiotic exposure during the earliest time window (<6 months) was consistently associated with increased body mass (+0.105 and +0.083 s.d. unit, increase in weight-for-length Z-scores at 10 and 20 months, P<0.001 and P=0.001, respectively; body mass index (BMI) Z-score at 38 months +0.067 s.d. units, P=0.009; overweight OR 1.22 at 38 months, P=0.029) in multivariable, mixed-effect models controlling for known social and behavioral obesity risk factors. Exposure from 6 to 14 months showed no association with body mass, while exposure from 15 to 23 months was significantly associated with increased BMI Z-score at 7 years (+0.049 s.d. units, P=0.050). Exposures to non-antibiotic medications were not associated with body mass.
Exposure to antibiotics during the first 6 months of life is associated with consistent increases in body mass from 10 to 38 months. Exposures later in infancy (6-14 months, 15-23 months) are not consistently associated with increased body mass. Although effects of early exposures are modest at the individual level, they could have substantial consequences for population health. Given the prevalence of antibiotic exposures in infants, and in light of the growing concerns about childhood obesity, further studies are needed to isolate effects and define life-course implications for body mass and cardiovascular risks.
研究生命最初 2 年内抗生素暴露与生命最初 7 年内体重增长的相关性。
纵向出生队列研究。
11532 名在英国埃文于 1991-1992 年出生的体重≥2500 克的个体,他们均为“儿童父母纵向研究”(ALSPAC)中的人群研究对象。
三个不同的早期生命时间窗(<6 个月、6-14 个月、15-23 个月)期间的抗生素暴露情况,以及五个时间点(6 周、10 个月、20 个月、38 个月和 7 岁)的体重指数。
生命最初时间窗(<6 个月)的抗生素暴露与体重持续增加相关(10 个月和 20 个月时体重长度 Z 分数增加 0.105 和 0.083 个标准差单位,P<0.001 和 P=0.001;38 个月时体重指数 Z 分数增加 0.067 个标准差单位,P=0.009;38 个月时超重 OR 1.22,P=0.029),在控制已知的社会和行为肥胖风险因素的多变量混合效应模型中。6-14 个月的暴露与体重无相关性,而 15-23 个月的暴露与 7 岁时 BMI Z 分数增加显著相关(0.049 个标准差单位,P=0.050)。非抗生素药物的暴露与体重无关。
生命最初 6 个月期间的抗生素暴露与 10-38 个月时的体重持续增加有关。婴儿期后期(6-14 个月、15-23 个月)的暴露与体重增加不相关。虽然个体水平上的早期暴露效应较小,但对人群健康可能有重大影响。鉴于婴儿抗生素暴露的普遍性,以及对儿童肥胖问题的日益关注,需要进一步研究以分离这些影响,并明确生命过程对体重和心血管风险的影响。